NBIX

Neurocrine Biosciences Inc

Add to Watchlist

Advanced Chart

125.010

-0.59(-0.470%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

126.440

Open

125.500

VWAP

124.69

Vol

1.05M

Mkt Cap

12.40B

Low

123.670

Amount

130.73M

EV/EBITDA(TTM)

21.65

Total Shares

100.64M

11.42B

EV/OCF(TTM)

20.14

P/S(TTM)

5.11

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

736.52M

+28.63%

1.966

+180.84%

784.32M

+24.95%

2.369

+40.15%

749.14M

+20.42%

2.108

+16.45%

Estimates Revision

The market is revising Upward the revenue expectations for Neurocrine Biosciences, Inc. (NBIX) for FY2025, with the revenue forecasts being adjusted by 3.76% over the past three months. During the same period, the stock price has changed by 3.80%.

Revenue Estimates for FY2025

Revise Upward

+3.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.32%

In Past 3 Month

Stock Price

Go Up

+3.80%

In Past 3 Month

25 Analyst Rating

33.38% Upside

Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 166.74 USD with a low forecast of 124.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

22 Buy

3 Hold

0 Sell

Strong Buy

33.38% Upside

Current: 125.010

Low

124.00

Averages

166.74

High

200.00

33.38% Upside

Current: 125.010

Low

124.00

Averages

166.74

High

200.00

Guggenheim

Yatin Suneja

Buy

maintain

$165 -> $175

2025-08-01

Reason

Guggenheim

Yatin Suneja

Price Target

$165 -> $175

2025-08-01

maintain

Buy

Reason

Guggenheim analyst Yatin Suneja raised the firm's price target on Neurocrine to $175 from $165 and keeps a Buy rating on the shares. Non-GAAP EPS came in above the Street's forecast and the company narrowed FY25 Ingrezza sales guidance to $2.5-$2.55B, notes the analyst, who calls out the Phase 2 readout in MDD with NBI-770 and Phase 3 readouts in Dyskinetic Cerebral Palsy, both due in Q4, as the next key catalysts for Neurocrine.

Morgan Stanley

Overweight

maintain

$148 -> $150

2025-07-22

Reason

Morgan Stanley

Price Target

$148 -> $150

2025-07-22

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Neurocrine to $150 from $148 and keeps an Overweight rating on the shares ahead of the company reporting Q2 results on July 30. The firm projects Q2 Ingrezza sales of $630M, aligning with consensus, and estimates Crenessity sales of $20M, slightly below the $23M consensus, the analyst noted. However, the firm continues to see "under-appreciated value in 2H and beyond," the analyst added in the firm's preview.

Truist

Danielle Brill

initiated

$163

2025-07-21

Reason

Truist

Danielle Brill

Price Target

$163

2025-07-21

initiated

Reason

Truist analyst Danielle Brill initiated coverage of Neurocrine with a Buy rating and $163 price target. Despite headwinds in the marketplace, the firm is "confident" in the outlook for the base Ingrezza business and views the Crenessity launch as the key growth driver over the next 12-plus months, the analyst tells investors. In addition, the remaining pipeline is "high-risk," but all potential upside to the firm's model, the analyst added.

Goldman Sachs

NULL -> Buy

initiated

$182

2025-07-10

Reason

Goldman Sachs

Price Target

$182

2025-07-10

initiated

NULL -> Buy

Reason

Goldman Sachs initiated coverage of Neurocrine with a Buy rating and $182 price target, implying 36% upside potential. The firm says Neurocrine has an attractive growth profile relative to its mid-cap peers, given the ongoing Crenessity launch. The company offers significant upside on positive clinical development over the next several years, the analyst tells investors in a research note.

UBS

Buy

maintain

$152 -> $174

2025-07-09

Reason

UBS

Price Target

$152 -> $174

2025-07-09

maintain

Buy

Reason

UBS raised the firm's price target on Neurocrine to $174 from $152 and keeps a Buy rating on the shares. UBS continues to see steady upside on the stock for remainder of 2025, and tells investors in a research note that for the stock to break from the recent range-bound action, consistently strong uptake on Crenessity is key. The stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24, UBS argues.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$185 → $168

2025-04-22

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$185 → $168

2025-04-22

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Neurocrine Biosciences Inc (NBIX.O) is 14.76, compared to its 5-year average forward P/E of 22.51. For a more detailed relative valuation and DCF analysis to assess Neurocrine Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

22.51

Current PE

14.76

Overvalued PE

27.86

Undervalued PE

17.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

23.25

Current EV/EBITDA

16.63

Overvalued EV/EBITDA

31.05

Undervalued EV/EBITDA

15.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

6.02

Current PS

4.04

Overvalued PS

7.26

Undervalued PS

4.78